EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Liquid Biopsy Biomarkers in Endometrial Cancer: Current Landscape and Future Perspectives

Walter Giuseppe Giordano iD, Ludovica Pepe, Canio Martinelli iD, Valeria Zuccalà iD, Giuliana Ciappina iD, Massimiliano Berretta iD, Giuseppe Giuffrè, Vincenzo Fiorentino iD, Antonio Ieni iD

Biomolecules · 2026

DOI: 10.3390/biom16060911 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2026. Verfasst von Walter Giuseppe Giordano und 8 weiteren Autor:innen. Beteiligte Einrichtung: PhD Program in Translational Molecular Medicine and Surgery, Department of Biomedical Sciences, Dental Sciences and Morpho-Functional Imaging, Univer…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial cancer is the most common gynecologic malignancy in developed countries and remains challenging in terms of risk stratification, treatment monitoring, and early detection of recurrence. Liquid biopsy provides a minimally invasive approach for the dynamic assessment of tumor-derived biomarkers and may complement tissue-based diagnosis and molecular classification. This narrative review summarizes current evidence on circulating biomarkers in endometrial cancer, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), circulating microRNAs, and tumor-educated platelets, with attention to validity, applicability, and implementation barriers. Among these biomarkers, ctDNA currently has the strongest evidence base, especially for longitudinal monitoring, prognostic stratification, molecular residual disease assessment, and early detection of relapse in high-risk or recurrent disease. However, its sensitivity remains limited in early-stage, low-volume, and low-shedding tumors. CTCs, EVs, microRNAs, and platelet-derived signatures are promising but still largely investigational. Artificial intelligence may support multimodal biomarker validation, although clinical adoption will require external validation, locked algorithms, standardized workflows, and prospective utility trials. Overall, liquid biopsy represents a promising adjunct to tissue-based diagnosis and molecular classification in endometrial cancer, particularly for monitoring and follow-up. Prospective studies are now needed to demonstrate whether liquid-biopsy-informed decisions can improve outcomes or safely reduce overtreatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsBiomarkers, TumorHumansFemaleLiquid BiopsyNeoplastic Cells, CirculatingCirculating Tumor DNAMicroRNAsExtracellular VesiclesPrognosis

Stichwörter der Autor:innen

artificial intelligencecirculating tumor DNA (ctDNA)circulating tumor cells (CTCs)clinical trialsendometrial cancerextracellular vesicles (EVs)liquid biopsymicroRNAsprecision oncology

Substanzen

Biomarkers, TumorCirculating Tumor DNAMicroRNAs

Autor:innen und Institutionen

  • PhD Program in Translational Molecular Medicine and Surgery, Department of Biomedical Sciences, Dental Sciences and Morpho-Functional Imaging, University of Messina, 98125 Messina, Italy.
  • Anatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
  • Unit of Obstetrics and Gynecology, Department of Human Pathology of Adult and Childhood "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
  • Sbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology, College of Science and Technology, Temple University, 1900 N 12 St, Philadelphia, PA 19122, USA.
  • Section of Experimental Medicine, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy.
  • Medical Oncology Unit, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.

ORCID-Profile: Walter Giuseppe Giordano, Canio Martinelli, Valeria Zuccalà, Giuliana Ciappina, Massimiliano Berretta, Vincenzo Fiorentino, Antonio Ieni

Zitieren

APA

Giordano, W. G., Pepe, L., Martinelli, C., Zuccalà, V., Ciappina, G., Berretta, M., Giuffrè, G., Fiorentino, V., & Ieni, A. (2026). Liquid Biopsy Biomarkers in Endometrial Cancer: Current Landscape and Future Perspectives. Biomolecules. https://doi.org/10.3390/biom16060911

Vancouver

Giordano WG, Pepe L, Martinelli C, Zuccalà V, Ciappina G, Berretta M, et al. Liquid Biopsy Biomarkers in Endometrial Cancer: Current Landscape and Future Perspectives. Biomolecules. 2026. doi:10.3390/biom16060911

BibTeX
@article{Giordano2026,
  author = {Giordano, Walter Giuseppe and Pepe, Ludovica and Martinelli, Canio and Zuccalà, Valeria and Ciappina, Giuliana and Berretta, Massimiliano and Giuffrè, Giuseppe and Fiorentino, Vincenzo and Ieni, Antonio},
  title = {Liquid Biopsy Biomarkers in Endometrial Cancer: Current Landscape and Future Perspectives},
  journal = {Biomolecules},
  year = {2026},
  doi = {10.3390/biom16060911}
}
Kostenlos starten →